Press Release

Zetagen Receives Approval in Australia to Begin Pilot Study of ZetaFuse® Bone Graft to Treat Cervical Degenerative Disc Disease

6 November 2023
  • Randomized, open-label, two-level cervical study will examine safety and efficacy of using ZetaFuse® in patients being treated with anterior cervical discectomy and fusion (ACDF) surgery.   
  • ZetaFuse® is a synthetic, small molecule, osteo-inductive biologic, designed to aid bone healing of spinal fusions. 
  • ZetaFuse® was granted FDA Breakthrough Device Designation for treatment of the complete spinal column, inclusive of the cervical, thoracic, and lumbar regions.

November 6, 2023, (Syracuse, New York) - Zetagen Therapeutics, a private, clinical-stage, biopharmaceutical company focused on driving breakthrough innovation in the treatment of metastatic cancers to bone and soft tissue organs as well as osteologic interventions, today announced its approval from the Human Research Ethics Committee (HREC) of Australia to begin a pilot study using its novel therapy ZetaFuse® bone graft for the treatment of cervical degenerative disc disease. The pilot study is a randomized, open-label, two-level cervical program which will examine the safety and efficacy of ZetaFuse® bone graft in patients undergoing anterior cervical discectomy and fusion (ADCF) surgery.

“We are pleased to begin this pilot study in Australia,” said Joe C. Loy, CEO of Zetagen Therapeutics. “If successful, ZetaFuse® will be another asset to our growing pipeline of therapies focused on serious osteologic issues ranging from lytic lesions in metastatic cancers to various skeletal related events.”

“For patients living with cervical degenerative disc disease, ACDF surgery is an option to relieve pain and stabilize the spine,” said Nikhil Thakur, MD, co-founder, and Chief Medical Officer of Zetagen Therapeutics. “Our hope is that by introducing ZetaFuse® bone graft as part of the ACDF surgical procedure we can empower spine surgeons with a safe, osteoinductive treatment option.”

ZetaFuse®, is a synthetic, small-molecule, osteo-inductive biologic technology being developed to aid in bone healing of spinal fusions. It works through a mechanism of action (MOA) which is a novel and patented molecular pathway. When the pathway is activated, it stimulates stem cells, activating cells to grow healthy bone known as “osteoblasts”, and inhibits cells associated with bone degradation called “osteoclasts”, preventing bone resorption.

ZetaFuse® was granted Breakthrough Device Designation status in 2021 from the U.S. Food and Drug Administration (FDA) for spinal fusion procedures including interbody fusion in the anterior cervical, thoracic, and lumbar spine or posterior fusions in the cervical, thoracic, and lumbar spine.

In the United States, interbody spinal fusion surgeries are the most commonly performed spinal procedures, stemming often from diagnoses of lumbar degenerative disc disease and cervical disc replacement. In the last 20 years, spinal fusion procedures have increased nearly two-fold, with an estimated 450,000 lumbar and 150,000 cervical spinal fusion procedures performed annually.[1]

The two year study will enroll 10 patients and be conducted at Prince of Wales Hospital and Prince of Wales Private Hospital in Australia.

[1] J Spine Surg 2020;6(4):752-761 |

All News

About zetagen Therapeutics

Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company dedicated to developing breakthrough therapies via local administration for metastatic and primary cancers to bone and other organs.

The company's pipeline encompasses several oncological candidates targeting metastatic and primary cancers for breast, lung, brain, prostate, and sarcomas with such drugs as ZetaMet™ (Zeta-BC-003), ZetaMet-P™ (Zeta-PC-004) and ZetaMAST™ (Zeta-MBC-005).

Forward-Looking Statements

This press release contains certain forward-looking statements with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Source: Zetagen Therapeutics, Inc.
Source: Zetagen Therapeutics, Inc.
SUNY Biotech Accelerator
841 E Fayette Street, Suite 1100
Syracuse, NY 13210
Investor Inquiries:
Zetagen Therapeutics, Inc.

Media Inquiries:
Mog & Springer Communications on Behalf of Zetagen Therapeutics, Inc.
Elizabeth Harness, Principal
Phone: +1-585-435-7379